Summary of subject immune response to mRNA COVID-19 vaccination and recall response to measles antigen
| Subject ID . | Age, y/sex . | Vaccine . | Response to mRNA COVID-19 vaccine . | Response to measles . | Treatment . | CD20 Ab . | ALC 1-4.8* . | IgG 700-1600 mg/dL* . | CD19+ 4-17%* . | IgD−CD27+ 5-21%* . | CD4 30-60%* . | CD8 10-30%* . | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ab . | CD4 . | CD8 . | MBC . | Ab . | MBC . | |||||||||||
| 1 | 62/Male | P | — | — | — | — | — | — | N | No | 48.00 | 85 | 96.00 | 3.60 | 2.00 | 0.70 |
| 2 | 63/Female | P | — | — | + | — | + | + | N | No | 21.00 | NA | 76.00 | 59.00 | 9.30 | 10.00 |
| 3 | 48/Male | ? | + | + | — | — | — | — | C | Yes (≤12) | 1.00 | NA | 2.10 | 17.00 | 39.00 | 33.00 |
| 4 | 77/Female | M | — | - | — | — | + | — | N | No | 87.00 | 573 | NA | NA | NA | NA |
| 5 | 81/Female | P | — | - | + | — | + | + | C | Yes (>12) | 5.80 | NA | NA | NA | 19.00 | 3.80 |
| 6 | 67/Male | M | — | + | + | — | + | + | C | No | 2.90 | 918 | 30.00 | 2.30 | 41.00 | 19.00 |
| 7 | 60/Female | P | — | + | + | — | + | — | O (6) | Yes (>12) | 1.60 | NA | 0.00 | 0.00 | 86.00 | 8.00 |
| 8 | 66/Male | P | — | - | — | — | + | — | C | Yes (>12) | 0.43 | 526 | 3.00 | 22.00 | 35.00 | 47.00 |
| 9 | 65/Female | ? | — | + | + | — | + | — | C | Yes (≤12) | 1.30 | NA | 0.07 | 0.00 | 62.00 | 21.00 |
| 10 | 62/Female | P | — | + | - | — | — | — | C | Yes (>12) | 30.00 | 262 | 65.00 | 2.40 | 23.00 | 8.00 |
| 11 | 63/Male | P | + | + | + | — | + | + | N | No | 17.00 | 780 | 83.00 | 0.21 | 13.00 | 2.10 |
| 12 | 61/Male | P | + | + | + | — | + | — | O (6-12) | Yes (>12) | 0.75 | 593 | 8.00 | 3.80 | 42.00 | 15.00 |
| 13 | 70/Male | P | — | + | — | — | + | — | C | Yes (>12) | 5.80 | 101 | 45.00 | 1.50 | 20.00 | 20.00 |
| 14 | 65/Male | P | — | + | — | — | + | — | O (>12) | Yes (>12) | 0.33 | 405 | NA | NA | 77.00 | 9.30 |
| 15 | 64/Male | M | — | — | + | — | + | — | C | Yes (>12) | 1.70 | 100 | 0.41 | 0.94 | 26.00 | 42.00 |
| 16 | 75/Male | P | + | + | + | — | + | — | O (>12) | Yes (>12) | 0.29 | 547 | 0.10 | 0.00 | 22.00 | 19.00 |
| Subject ID . | Age, y/sex . | Vaccine . | Response to mRNA COVID-19 vaccine . | Response to measles . | Treatment . | CD20 Ab . | ALC 1-4.8* . | IgG 700-1600 mg/dL* . | CD19+ 4-17%* . | IgD−CD27+ 5-21%* . | CD4 30-60%* . | CD8 10-30%* . | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ab . | CD4 . | CD8 . | MBC . | Ab . | MBC . | |||||||||||
| 1 | 62/Male | P | — | — | — | — | — | — | N | No | 48.00 | 85 | 96.00 | 3.60 | 2.00 | 0.70 |
| 2 | 63/Female | P | — | — | + | — | + | + | N | No | 21.00 | NA | 76.00 | 59.00 | 9.30 | 10.00 |
| 3 | 48/Male | ? | + | + | — | — | — | — | C | Yes (≤12) | 1.00 | NA | 2.10 | 17.00 | 39.00 | 33.00 |
| 4 | 77/Female | M | — | - | — | — | + | — | N | No | 87.00 | 573 | NA | NA | NA | NA |
| 5 | 81/Female | P | — | - | + | — | + | + | C | Yes (>12) | 5.80 | NA | NA | NA | 19.00 | 3.80 |
| 6 | 67/Male | M | — | + | + | — | + | + | C | No | 2.90 | 918 | 30.00 | 2.30 | 41.00 | 19.00 |
| 7 | 60/Female | P | — | + | + | — | + | — | O (6) | Yes (>12) | 1.60 | NA | 0.00 | 0.00 | 86.00 | 8.00 |
| 8 | 66/Male | P | — | - | — | — | + | — | C | Yes (>12) | 0.43 | 526 | 3.00 | 22.00 | 35.00 | 47.00 |
| 9 | 65/Female | ? | — | + | + | — | + | — | C | Yes (≤12) | 1.30 | NA | 0.07 | 0.00 | 62.00 | 21.00 |
| 10 | 62/Female | P | — | + | - | — | — | — | C | Yes (>12) | 30.00 | 262 | 65.00 | 2.40 | 23.00 | 8.00 |
| 11 | 63/Male | P | + | + | + | — | + | + | N | No | 17.00 | 780 | 83.00 | 0.21 | 13.00 | 2.10 |
| 12 | 61/Male | P | + | + | + | — | + | — | O (6-12) | Yes (>12) | 0.75 | 593 | 8.00 | 3.80 | 42.00 | 15.00 |
| 13 | 70/Male | P | — | + | — | — | + | — | C | Yes (>12) | 5.80 | 101 | 45.00 | 1.50 | 20.00 | 20.00 |
| 14 | 65/Male | P | — | + | — | — | + | — | O (>12) | Yes (>12) | 0.33 | 405 | NA | NA | 77.00 | 9.30 |
| 15 | 64/Male | M | — | — | + | — | + | — | C | Yes (>12) | 1.70 | 100 | 0.41 | 0.94 | 26.00 | 42.00 |
| 16 | 75/Male | P | + | + | + | — | + | — | O (>12) | Yes (>12) | 0.29 | 547 | 0.10 | 0.00 | 22.00 | 19.00 |
For T-cell–specific responses, “+” indicates an increase in S-specific T cells compared with baseline and “—“ indicates no change (or a decrease) in S-specific T cells following vaccination. Current treatment status, CD20 Ab treatment, and clinical values were recorded at baseline (time of enrollment) when available.
Ab, antibody; ALC, absolute lymphocyte count; C, currently on treatment; M, Moderna; N, treatment naive; NA, baseline values were not available; O (6), observation, last treatment within 6 months; O (6-12), observation, 6 to 12 months since last treatment; O (>12), observation, >12 months since last treatment; P, Pfizer-BioNTech; ?, unknown; +, response above the LOD; —, response below the LOD.
Normal range.